Tumour heterogeneity and a long-standing paucity of effective therapies other than
chemotherapy have contributed to triple-negative breast cancer (TNBC) being the subtype …

Major histocompatibility class I (MHC I) molecules bind peptides derived from a cell's
expressed genes and then transport and display this antigenic information on the cell …

Over the past few decades, RNA sequencing has significantly progressed, becoming a
paramount approach for transcriptome profiling. The revolution from bulk RNA sequencing …

Triple‑negative breast cancer (TNBC) accounts for 10‑15% of all breast cancer cases.
TNBCs lack estrogen and progesterone receptors and express low levels of HER2, and …

Breast cancer, the most common type of cancer affecting women, encompasses a collection
of histologic (mainly ductal and lobular) and molecular subtypes exhibiting diverse clinical …

Immunotherapy is emerging as a new treatment modality in breast cancer. After long-
standing use of endocrine therapy and targeted biological therapy, improved understanding …

Regulatory programs that control the function of stem cells are active in cancer and confer
properties that promote progression and therapy resistance. However, the impact of a stem …

Purpose: The tumor microenvironment has a profound impact on prognosis and
immunotherapy. However, the landscape of the triple-negative breast cancer (TNBC) …

Background Little is known about how the immune microenvironment of breast cancer
evolves during disease progression. Patients and methods We compared tumor infiltrating …

Background Abundant evidence shows that triple-negative breast cancer (TNBC) is
heterogeneous, and many efforts have been devoted to identifying TNBC subtypes on the …